BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 10876191)

  • 1. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
    Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
    Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
    Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.
    González-Yebra B; Medrano ME; Mantilla A; Palma V; Colin C; Hernández DM; Tapia J; Dawson B; Salcedo M
    Endocr Pathol; 2003; 14(1):71-80. PubMed ID: 12746565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome?
    Hansen HS; Torring H; Godballe C; Jäger AC; Nielsen FC
    Cancer; 2000 Aug; 89(4):863-7. PubMed ID: 10951350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
    González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
    Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.
    Dvorakova S; Vaclavikova E; Duskova J; Vlcek P; Ryska A; Bendlova B
    J Endocrinol Invest; 2005 Nov; 28(10):905-9. PubMed ID: 16419493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
    Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
    Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.
    Niccoli-Sire P; Murat A; Rohmer V; Franc S; Chabrier G; Baldet L; Maes B; Savagner F; Giraud S; Bezieau S; Kottler ML; Morange S; Conte-Devolx B;
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3746-53. PubMed ID: 11502806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation of RET codon 768 is associated with the FMTC phenotype.
    Boccia LM; Green JS; Joyce C; Eng C; Taylor SA; Mulligan LM
    Clin Genet; 1997 Feb; 51(2):81-5. PubMed ID: 9111992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.
    Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK
    Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.
    Oriola J; Páramo C; Halperin I; García-Mayor RV; Rivera-Fillat F
    Am J Med Genet; 1998 Jul; 78(3):271-3. PubMed ID: 9677065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.